Table 5. The relation between risk-group and clinical parameter.
The high-risk proportion was significantly larger associated with a higher T-stage, N-stage, and Stage.
| Variables | TCGA Low risk | TCGA High risk | P-value | GSE50081 Low risk | GSE50081 High risk | P-value | ||
|---|---|---|---|---|---|---|---|---|
| All | 159 | 158 | 64 | 63 | ||||
| Age | 0.948 | 0.932 | ||||||
| <65y | 69 (50.7%) | 67 (49.3%) | <70y | 30 (49.2%) | 31 (50.8%) | |||
| ≥65y | 90 (49.7%) | 91 (50.3%) | ≥70y | 34 (51.5%) | 32 (48.5%) | |||
| Gender | 0.049 | 1.000 | ||||||
| male | 68 (44.2%) | 86 (55.8%) | male | 33 (50.8%) | 32 (49.2%) | |||
| female | 91 (55.8%) | 72 (44.2%) | female | 31 (50.0%) | 31 (50.0%) | |||
| T-stage | <0.001 | 0.004 | ||||||
| T1 | 66 (67.3%) | 32 (32.7%) | T1 | 30 (69.8%) | 13 (30.2%) | |||
| T2 | 81 (45.0%) | 99 (55.0%) | T2 | 34 (41.5%) | 48 (58.5%) | |||
| T3+4 | 12 (30.8%) | 27 (69.2%) | T3+4 | 0 | 2 (100%) | |||
| N-stage | 0.002 | 0.013 | ||||||
| N0 | 116 (57.1%) | 87 (42.9%) | N0 | 54 (57.4%) | 40 (42.6%) | |||
| N1 | 28 (41.8%) | 39 (58.2%) | N1 | 10 (30.3%) | 23 (69.7%) | |||
| N2 | 15 (31.9%) | 32 (68.1%) | ||||||
| Stage | 0.001 | 0.005 | ||||||
| I | 102 (59.3%) | 70 (40.7%) | I | 54 (58.7%) | 38 (41.3%) | |||
| II | 37 (43.0%) | 49 (57.0%) | II | 10 (28.6%) | 25 (71.4%) | |||
| III | 20 (33.9%) | 39 (66.1%) |